Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender
• People who have been diagnosed with a blood cancer that is CD19-positive (a specific protein found on cancer cells) and has come back or stopped responding to treatment, confirmed by laboratory testing under 2022 World Health Organization guidelines
• People with a general health and activity level rated as reasonably functional (a standard medical score of 0, 1, or 2 on a scale used by doctors to measure how much a condition affects daily activities)
• People with a life expectancy of at least 3 months
• People who have no medical reasons preventing a procedure to collect white blood cells from the blood (called leukapheresis)
• People whose cancer cells have been confirmed to carry the CD19 protein, shown through specific laboratory tests
• People without serious problems affecting the heart, lungs, liver, or kidneys
• People who are able to understand the study and are willing to sign a consent form

Who may not be able to join:

• People with a known allergy to any ingredient in the cell-based treatment being studied
• People whose blood test results show that certain blood cell counts are too low (white blood cells, neutrophils, lymphocytes, or platelets are below specific levels)
• People whose blood tests show the liver or kidneys are not working well enough, based on specific chemical levels in the blood
• People with significant heart failure classified at a severe level, or whose heart pumping function is below 50% as measured by an ultrasound of the heart
• People whose lungs are not working well enough, shown by blood oxygen levels below 92% while breathing normal room air
• People who have had a heart attack, heart procedure, unstable chest pain, or another serious heart condition within the 12 months before joining
• People with severely high blood pressure that has not been brought under control despite taking medication
• People with a history of brain injury, loss of consciousness, epilepsy (seizures), serious lack of blood supply to the brain, or bleeding in the brain
• People with an autoimmune disease, a weakened immune system, or any condition that requires ongoing treatment with medicines that suppress the immune system
• People with an active infection that is not under control
• People who have previously received CAR-T cell therapy or any other treatment involving genetically modified T-cells
• People who have received a live vaccine within 4 weeks before joining the trial
• People who test positive for HIV, hepatitis B, hepatitis C, or syphilis, or who are carriers of hepatitis B
• People with a history of alcohol misuse, drug misuse, or a psychiatric illness
• People who have taken part in another clinical trial within 3 months before joining this study
• Women who are pregnant or breastfeeding, planning to become pregnant during the study, or who are able to become pregnant and are unwilling or unable to use effective contraception
• People who, in the opinion of the trial doctor, have any other condition that makes participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.